Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives

Journal of Human Hypertension

Volumn 22, Issue 11, 2008, Pages 774-780

  Bozkurt, O ^a   Verschuren, W M M ^b   van Wieren de Wijer, B M A ^a   Knol, M J ^c   de Boer, A ^a   Grobbee, D E ^c   Geerlings, M I ^c   Heerdink, E R ^a   Klungel, O H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; RENIN; THIAZIDE DIURETIC AGENT;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENE DELETION; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHARMACOGENETICS; PHYSICAL EXAMINATION; QUESTIONNAIRE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR;

ALLELES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; DIABETES MELLITUS; DNA; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; HYPERTENSION; INCIDENCE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 54249131592     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.62     Document Type: Article

References (22)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-1428.
2. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007; 369(9557): 201-207.
3. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23(3): 463-473.
4. Verschuren WMM, van Leer EM, Blokstra A, Seidell JC, Smit HA, Bueno de Mesquita HB et al. Cardiovascular disease risk factors in the Netherlands. Neth J Cardiol 1993; 4: 205-210.
5. Lievers KJA, de Boer A, Stricker BHCh, de Wijer BMA, Kroon AA, de Leeuw PW et al. Interactions between genetic polymorphisms and antihypertensive drugs in the treatment of hypertension. Eur J Hum Genet 2004; 12(1): 303.
6. Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the hypertension-associated Met235 → Thr allele of the human angiotensinogen gene. Hum Mol Genet 1993; 2(5): 609-610.
7. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86(4): 1343-1346.
8. Henskens LH, Spiering W, Stoffers HE, Soomers FL, Vlietinck RF, de Leeuw PW et al. Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: First results of the Hippocates study. J Hypertens 2003; 21(1): 81-86.
9. Knaapen AM, Ketelslegers HB, Gottschalk RW, Janssen RG, Paulussen AD, Smeets HJ et al. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension. Clin Chem 2004; 50(9): 1664-1668.
10. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002; 20(10): 2023-2027.
11. World Health Organization. Guidelines for ATC Classification and DDD Assignment. WHO Collaborating Centre for Drug Statistics Methodology - Nordic Council on Medicines: Oslo, 1999.
12. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996; 58(6): 1268-1278.
13. Rothman K, Greenland S. Modern Epidemiology, 2nd edn. Lippincott/ Raven: Philadelphia, PA, USA, 1998.
14. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: Case-control studies with no controls!. Am J Epidemiol 1996; 144(3): 207-213.
15. Yu HM, Lin SG, Liu GZ, Zhang YQ, Ma WJ, Deng CY. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin Pharmacol Ther 2006; 79(6): 581-589.
16. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54(4): 991-999.
17. Schelleman H, Stricker BH, De Boer A, Kroon AA, Verschuren MW, Van Duijn CM et al. Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004; 64(16): 1801-1816.
18. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51(1): 197-205.
19. Rett K, Lotz N, Wicklmayr M, Fink E, Jauch KW, Gunther B et al. [Improved insulin action by ACE inhibition in type-2 diabetics]. Dtsch Med Wochenschr 1988; 113(7): 243-249.
20. Huang XH, Rantalaiho V, Wirta O, Pasternack A, Koivula T, Hiltunen T et al. Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM. Hum Genet 1998; 102(3): 372-378.
21. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis. Arterioscler Thromb Vasc Biol 2003; 23(7): 1269-1275.
22. Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol Regul Integr Comp Physiol 2001; 281(3): R795-R802.